Precision Immunotherapy™
investors-relations
Investor Relations

Email Alerts

Email Address *
Mailing Lists *






Opexa Therapeutics to Present at the 6th Annual European Life Science CEO Forum

03/04/2013

THE WOODLANDS, Texas (March 04, 2013) – Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tcelna™, a novel T-cell therapy for multiple sclerosis (MS), today announced that Neil K. Warma, President and Chief Executive Officer, will present at the 6th Annual European Life Science CEO Forum on Tuesday, March 5, 2013, at 2:30 p.m. CET. The conference will be held at the Hilton Zurich Airport Hotel in Zurich, Switzerland.

About Opexa

Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as MS. The Company’s leading therapy, Tcelna™, is a personalized cellular immunotherapy treatment that is in late stage clinical development for MS. Tcelna is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin and, thereby, reduces the risk of relapse over time. For more information visit the Opexa Therapeutics website at www.opexatherapeutics com

Contacts:
Neil K. Warma
Opexa Therapeutics, Inc.
President & CEO
281-775-0600
nwarma@opexatherapeutics.com

Investor Relations:
The Trout Group
Adam Cutler
646-378-2936
opexa@troutgroup.com